ClinicalTrials.gg
RecruitingNCT05994976Updated Oct 28, 2026

Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

An observational study in Acne, Atopic Dermatitis and Chronic Hand Eczema, sponsored by Innovaderm Research Inc.. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Innovaderm Research Inc. · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies in Acne Vulgaris with a site in Canada — 4 open to participants now, 5 under way, none of them phase 3. Acne Vulgaris · Canada.

Started
2023
the only one that year
Observational
3 of 59
1 open now
Registered
53rd of 59
by date
Lead sponsor
2 of 59
Innovaderm Research Inc.

Among the 59 studies in Acne Vulgaris with a site in Canada, this one is the only one that started in 2023, is one of 3 observational ones, and was the 53rd registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

4 of the 59 studies in Acne Vulgaris with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Acne Vulgaris with a site in Canada, or all of them as a file.
02

Study summary

The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.

Read the detailed description

This study is being conducted to collect samples from subjects with various skin conditions as well as healthy volunteers. Collected samples may be used for different analyses including, but not limited to, biomarker and gene expression analyses.

03

Conditions studied

  • Acne
  • Atopic Dermatitis
  • Chronic Hand Eczema
  • Hidradenitis Suppurativa
  • Plaque Psoriasis
  • Palmoplantar Pustulosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Approximately 200 healthy volunteers and approximately 300 subjects with acne, atopic dermatitis (AD), chronic hand eczema (CHE), hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), and/or psoriasis will be included in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects:

  1. Subject is willing to participate and is capable of giving . Note: Consent must be obtained prior to any study-related procedures.
  2. Subject must be willing to comply with all study procedures and must be available for the duration of the study.

    Healthy volunteers:

  3. Male or female subject aged 18 years or older, at the time of consent.
  4. Subject is in good general health, according to the investigator's judgment.

    Subjects with Acne:

  5. Male or female subject aged 18 to 45 years old, inclusive, at the time of consent.

    Subjects with AD:

  6. Male or female subject aged 18 years or older, at the time of consent.
  7. Subject has clinically confirmed diagnosis of active AD, according to Hanifin and Rajka criteria.

    Subjects with CHE:

  8. Male or female subject aged 18 years or older, at the time of consent.
  9. Subject has at least a 6-month history of CHE before Screening (information obtained from medical chart or subject's physician, or directly from the subject).

    Subjects with HS:

  10. Male or female subject aged 18 years or older, at the time of consent.
  11. Subject has a clinically confirmed diagnosis of active HS with a disease duration of ≥ 6 months before screening as determined by the investigator through subject interview and/or review of the medical history.

    Subjects with PPP:

  12. Male or female subject aged 18 years or older at the time of consent.
  13. Subject has at least a 6-month history of PPP as defined by the presence of pustules on palms and/or soles, but without evidence of infection on palms and soles (information obtained from medical chart or subject's physician, or directly from the subject).

    Subjects with psoriasis:

  14. Male or female subject aged 18 years or older, at the time of consent.

Exclusion criteria

Exclusion Criteria:

All subjects:

  1. Subject is a female who is pregnant or who is planning to become pregnant during the study.
  2. Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Healthy volunteers

    Healthy adults

    Procedure: Blood samples collection · Procedure: Oral samples collection · Procedure: Hair samples collection · Procedure: Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping) · Procedure: Skin surface material samples · Procedure: Drainage fluid samples collection · Procedure: Stool samples collection

  • Acne

    Adult subjects aged 18 to 45 years old with acne

    Procedure: Blood samples collection · Procedure: Oral samples collection · Procedure: Hair samples collection · Procedure: Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping) · Procedure: Skin surface material samples · Procedure: Drainage fluid samples collection · Procedure: Stool samples collection

  • AD

    Adult subjects with Atopic Dermatitis (AD)

    Procedure: Blood samples collection · Procedure: Oral samples collection · Procedure: Hair samples collection · Procedure: Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping) · Procedure: Skin surface material samples · Procedure: Drainage fluid samples collection · Procedure: Stool samples collection

  • CHE

    Adult subjects with Chronic Hand Eczema (CHE)

    Procedure: Blood samples collection · Procedure: Oral samples collection · Procedure: Hair samples collection · Procedure: Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping) · Procedure: Skin surface material samples · Procedure: Drainage fluid samples collection · Procedure: Stool samples collection

  • HS

    Adult subjects with Hidradenitis suppurativa (HS)

    Procedure: Blood samples collection · Procedure: Oral samples collection · Procedure: Hair samples collection · Procedure: Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping) · Procedure: Skin surface material samples · Procedure: Drainage fluid samples collection · Procedure: Stool samples collection

  • PPP

    Adult subjects with Palmoplantar pustulosis (PPP)

    Procedure: Blood samples collection · Procedure: Oral samples collection · Procedure: Hair samples collection · Procedure: Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping) · Procedure: Skin surface material samples · Procedure: Drainage fluid samples collection · Procedure: Stool samples collection

  • Psoriasis

    Adult subjects with Psoriasis

    Procedure: Blood samples collection · Procedure: Oral samples collection · Procedure: Hair samples collection · Procedure: Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping) · Procedure: Skin surface material samples · Procedure: Drainage fluid samples collection · Procedure: Stool samples collection

Interventions

  • ProcedureBlood samples collection

    biomarkers and optional genetic analysis

  • ProcedureOral samples collection

    biomarkers analysis

  • ProcedureHair samples collection

    biomarkers analysis

  • ProcedureSkin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping)

    biomarkers analysis

  • ProcedureSkin surface material samples

    biomarkers analysis

  • ProcedureDrainage fluid samples collection

    biomarkers analysis

  • ProcedureStool samples collection

    biomarkers analysis

06

What researchers measure

Primary outcomes

  1. Untargeted biomarker approach with gene expression profile of skin samples

    Time frame: Day 1

  2. Exploratory biomarker and gene expression analyses.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Aug 2028, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Aug 16, 2023
StartActual
Oct 17, 2023
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • Innovaderm Research Inc. · Montreal, CanadaContact j•••@innovaderm.com · •••4285→v•••@inderocro.com · •••4285
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Innovaderm Research Inc. · Montreal, CanadaContact j•••@innovaderm.com · •••4285→v•••@inderocro.com · •••4285
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05994976
Lead sponsor
Innovaderm Research Inc.
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
Oct 17, 2023
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Julie Bedoucha, MSc
Contact
jbedoucha@innovaderm.com
514-521-4285 ext. 253
Robert Bissonnette, MD
principal investigator · Innovaderm Research Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion